Phase II Randomized Study of Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

Condition:   Bladder Cancer Interventions:   Drug: Olaparib;   Drug: Durvalumab Sponsor:   Latin American Cooperative Oncology Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials